![Stephen R. Donahue](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen R. Donahue
No más puestos en curso
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Oren M. Becker | M | - |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Mark Gabrielson | M | 68 | 3 años | |
James Fordyce | M | 81 | 1 años | |
Ben Palleiko | M | 58 | 1 años | |
Fredrick Frank | M | 92 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | 5 años |
David L. Urdal | M | 74 | 3 años | |
Ian Smith | M | 58 |
Predix Pharmaceuticals, Inc.
![]() Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | 1 años |
Julian Adams | M | 69 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Michael Kauffman | M | 60 |
Predix Pharmaceuticals, Inc.
![]() Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | 4 años |
Kimberlee Drapkin | F | 56 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | 1 años |
David Collier | M | 61 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Christine H. Wang | F | - |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Yigal Erlich | M | 84 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 13 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Stephen R. Donahue
- Red Personal